Report

Flash note: BL-8040 progressing in varied cancer types

BioLineRx’s lead compound, BL-8040, is under development in numerous cancer indications, for which we anticipate collective peak sales potential of c $700m. We also expect first launch of its skin lesion product by partner Perrigo in 2016 to yield royalties of c $2-3m per year.
Underlying
BioLine Rx Ltd

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch